Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
12.75    -0.25 (-1.92%)
Bid:
12.00
Ask:
13.50
Spread: 1.50 (12.50%)
Market Cap: £15.94m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Site Update

11 Nov 2008 07:00

RNS Number : 8653H
Fabian Romania Limited
11 November 2008
 

Fabian Romania Limited ("Fabian Romania" or the "Company")

Fabian Romania achieves Building Permit for "The Orchard" residential development site in Timisoara.

Fabian Romania along with its development partner Coltex Construct has been granted the building permit for its residential development scheme of 429 apartments in Timisoara.

The Orchard will provide 429 high quality apartments constructed in two phases, totalling 38,812 sqm with an additional 540 car spaces. 

Designed by international architects, Jestico Whiles, the Directors of Fabian Romania believe that it will provide a new degree of quality residential product not seen before in the local market. The site is located 10 minutes to the north west of Timisoara city centre in a residential neighbourhood with good access just off Strada Textilistolor, one of the main routes travelling north out of the city. 

Timisoara is built on the site of an historical Roman fortress. Over the years it has been influenced by many cultures and is now an important university city with strong links to its industrial heritage. The population has expanded rapidly over the last 10 years to over 300,000. International companies have invested in the city including Continental, Nestle and Procter & Gamble. As the wealth of the city has grown this has created demand for residential development.

Commenting on the transaction, Mark Owen, Property Director of Fabian Capital, the Company's Investment Manager said: 

"This has been a phased land acquisition and we are pleased to have achieved all the permits necessary to start construction. The scheme is an excellent design and well located just north of the city and close to existing retail shopping malls. In light of current market conditions we have secured the value of the site by obtaining these permits and will assess market conditions early next year and establish when the time is right for construction to commence."

Enquiries

 

Fabian Capital:

Anthony Foster +44 20 7499 9988

 

Deloitte Corporate Finance - Nominated Adviser to Fabian Romania

 

Mike Bell +44 20 7007 1463

 

Shore Capital Stockbrokers Limited - Joint Broker to Fabian Romania

 

Dru Danford +44 20 7408 2090

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXFEFLFPFFE
Date   Source Headline
2nd Jun 20267:00 amRNSExercise of options and total voting rights
11th May 20263:06 pmRNSHolding(s) in Company
11th May 202611:05 amRNSGrant of patent in Japan
5th May 20267:00 amRNSYear-end trading statement
30th Mar 20267:00 amRNSAntibody IP transfer agreement
17th Feb 202611:42 amRNSDirector/PDMR Shareholding
4th Feb 20263:27 pmRNSHolding(s) in Company
2nd Feb 202611:33 amRNSHolding(s) in Company
30th Jan 20265:00 pmRNSTotal Voting Rights
27th Jan 20267:05 amRNSIssue of Director Shares
27th Jan 20267:00 amRNSPlacing and Subscription to raise approx £1.4m
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
16th Dec 202511:04 amRNSLaunch of OptiMAL platform
11th Dec 20257:00 amRNS-RMammalian Display video
25th Nov 202512:11 pmRNSHolding(s) in Company
24th Nov 20257:00 amRNSHalf-year Financial Report
21st Nov 20257:00 amRNSNotice of Results
13th Nov 20257:00 amRNS-ROptiMAL Library video
3rd Nov 20257:00 amRNSOptiMAL® R&D Update
27th Oct 20253:38 pmRNSHolding(s) in Company
16th Oct 20251:31 pmRNSResult of AGM
16th Oct 20257:00 amRNSAGM statement and H1 trading update
8th Oct 20257:00 amRNSContract win
19th Sep 202512:58 pmRNSPosting of Annual Report & Notice of AGM
17th Sep 20257:00 amRNSOptiMAL R&D Update
8th Sep 20257:00 amRNS-RBelfast investor presentation
4th Sep 20257:00 amRNSFinal Results
28th Aug 20257:00 amRNSContract Win
27th Aug 20257:00 amRNSContract wins with existing client
26th Aug 20257:00 amRNS-RInvestor presentations
5th Aug 20257:00 amRNSGrant of U.S. Patent for OptiMAL
24th Jul 202510:56 amRNSIssue Notification: US Patent Update
11th Jul 20257:00 amRNSDirector/PDMR Shareholding
2nd Jun 20257:00 amRNSTotal Voting Rights
22nd May 20252:33 pmRNSUpdate on U.S. Patent for OptiMAL®
8th May 20257:00 amRNS-RInvestor presentation
7th May 20257:00 amRNSIssue of shares to non-executive directors
6th May 202510:53 amRNSDirector/PDMR Shareholding
6th May 202510:38 amRNSHolding(s) in Company
6th May 20257:00 amRNSTrading update
30th Apr 20255:00 pmRNSTotal Voting Rights
24th Apr 20257:00 amRNSApproval of grant funding
11th Apr 202510:40 amRNSHolding(s) in Company
10th Apr 202512:47 pmRNSHolding(s) in Company
7th Apr 202512:35 pmRNSResult of General Meeting
31st Mar 20255:00 pmRNSTotal Voting Rights
24th Mar 20254:38 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSPlacing to raise approximately £1.17 million
27th Feb 20257:00 amRNSContract win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.